Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is expected to be releasing its resultson Thursday, November 5th. Analysts expect the company to post earnings of ($0.1237) per share and revenue of $4.66 million for the quarter.
Carisma Therapeutics Trading Up 100.0%
CARM traded up $0.00 during trading hours on Tuesday, reaching $0.00. The company’s stock had a trading volume of 1,711 shares, compared to its average volume of 59,627. Carisma Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.10. The stock has a market cap of $16,738.00, a PE ratio of 0.00 and a beta of -9.60.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that harness and genetically engineer myeloid cells, including monocytes and macrophages, to treat cancer and other serious diseases. The company’s platform is designed to create engineered immune cells that can recognize disease-associated targets, enter solid tumors and alter the tumor microenvironment.
Carisma’s primary product candidate is CT-0525, an investigational HER2-targeted chimeric antigen receptor (CAR) monocyte therapy being developed for patients with advanced solid tumors.
Further Reading
- Five stocks we like better than Carisma Therapeutics
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
